Pulmonary Hypertension Functional Classification
Read about the different classes of the World Health Organization's (WHO) Pulmonary Hypertension Functional Classification.| Pulmonary Hypertension News
Read about the different classes of the World Health Organization's (WHO) Pulmonary Hypertension Functional Classification.| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
Study record managers: refer to the Data Element Definitions if submitting registration or results information.| clinicaltrials.gov
Marisa Wexler is a senior science writer for Pulmonary Hypertension News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
Pulmonary arterial hypertension (PAH) is a rare type of pulmonary hypertension that can be the result of one of several causes, or by no apparent cause. Read more information about PAH here.| Pulmonary Hypertension News
Some of the common symptoms of pulmonary hypertension include shortness of breath, excessive fatigue, weakness, chest pain, and fainting.| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News
